Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure equitable access to funding for IVF surrogacy for people post cancer treatment.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
Funding decisions for fertility services, including cases where a surrogate may be involved, are made by integrated care boards (ICBs), which are responsible for commissioning services based on the clinical needs of their populations. We expect ICBs to commission fertility services in line with National Institute for Health and Care Excellence (NICE) guidelines to support fair and consistent access across England.
NICE is currently reviewing the fertility guidelines and will consider whether its current recommendations for access to National Health Service funded treatment are still appropriate. A consultation on revised guidelines was published on 10 September and closed on 21 October 2025. The outcome of this review will support ICBs in making commissioning decisions that promote equitable access to fertility services, including for those whose fertility has been affected by medical treatment such as cancer.
Work continues between the Department and NHS England to analyse the current understanding and provision of NHS funded fertility services and address longstanding variation in access.
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when he expects the drug Vorsidenib (Voranigo) to be made available to treat adults and children aged 12 years and over with grade 2 astrocytoma or oligodendroglioma carrying a susceptible IDH1 or IDH2 mutation.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) is the independent body that makes evidence-based recommendations on whether new medicines should be routinely funded by the National Health Service based on an assessment of clinical and cost effectiveness. NICE is currently evaluating vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years old and over.
NICE published its draft guidance for consultation on 15 October and was unable to recommend it as a clinically and cost-effective use of NHS resources. The appraisal is still ongoing, and NICE will take the comments received fully into account in developing its final recommendations. The committee reviewed the consultation comments at the committee meeting on 20 November 2025. NICE currently expect to publish final guidance in January 2026.
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what his planned timeline is for the establishment of the naloxone supply network coordinators.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Naloxone is a lifesaving medicine that reverses the effects of an opioid overdose, including highly potent synthetic opioids which are growing in prevalence in the United Kingdom. It is more important than ever to increase access to naloxone products, which will save lives.
Last year, the Department amended the Human Medicines Regulations 2012 to further expand access to naloxone. The legislation enabled more services and professionals to supply this medication, making it easier to access for people at risk, and for their loved ones.
Route 1 of the legislation increased the number of services and professionals specified in regulations who can provide take home naloxone. However, not all services and professions had an agreed statutory definition across the four nations of the UK. As such, route 2 of the legislation set up the legal framework, which includes supply network coordinators, for the creation of a registration service for services and professions who fall outside the definitions listed in route 1 to apply and to be able to provide take home naloxone. These legislative changes were the first step in expanding access to naloxone, which has resulted in naloxone being more readily available to supply in the community. Since these changes came into effect, the Government has worked with the devolved administrations and front-line services to explore the set-up and delivery of this registration service. We have encountered operational difficulties in establishing supply network co-ordinators in England which has delayed implementation. However, we have identified further legislative amendments to increase access to take-home and emergency use naloxone and, as such, we intend to launch a public consultation by the end of this year.
The Department has also published guidance, Supplying take home naloxone without a prescription, that sets out essential practical information such as who can supply naloxone, the products available, how to use naloxone and other basic lifesaving tools, and the training required. This guidance is available at the following link:
https://www.gov.uk/guidance/supplying-take-home-naloxone-without-a-prescription
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to NHS England's plan entitled Cervical cancer elimination by 2040 – plan for England, published on 28 March 2025, if his Department will set out (a) who is responsible for each of the actions in that plan, (b) when those actions will be delivered by and (c) what the metrics are for success.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to improving vaccine uptake and access across all immunisation programmes by exploring new and innovative delivery models, including expanding routes such as community pharmacies, as set out in the NHS Vaccination Strategy and the 10-Year Health Plan for England.
In June, the UK National Screening Committee, which advises ministers on all aspects of screening, recommended a human papilloma virus (HPV) self-sampling option to women and people with a cervix who never or rarely attend routine cervical screening appointments. From early in 2026, they will receive home testing kits if they have not responded to a cervical screening invitation for a period of time. This will help tackle deeply entrenched barriers that keep some away from life-saving screening.
The World Health Organisation’s cervical cancer elimination targets will be used as the basis for ongoing monitoring, along with the regular assessment of cervical cancer rates.
NHS England will be monitoring and evaluating the success of all the individual activities included within its elimination plan, as well as new initiatives as they are developed and implemented.
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when the database of AstraZeneca covid-19 vaccine side effects was last updated.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Medicines and Healthcare products Regulatory Agency is responsible for monitoring all authorised medicines and vaccines in the United Kingdom, including the AstraZeneca COVID-19 vaccines, on an ongoing basis to ensure their benefits continue to outweigh any risks. This monitoring strategy is continuous, proactive, and based on a wide range of information sources, including reports of adverse events and rare side effects retrieved from the Yellow Card Database. A dedicated team of assessors reviews this information on a weekly basis to look for safety issues or unexpected, rare events.
The AstraZeneca COVID-19 vaccine no longer has an active market authorisation in the UK, since 2024. Consequently, no additional research activities have been undertaken beyond the ongoing monitoring of reported suspected adverse events through the Yellow Card Scheme. The most recent data extraction of spontaneous suspected adverse reactions reported via the Yellow Card Scheme was conducted on 20 September 2025. Further information is available at the following link:
https://yellowcard.mhra.gov.uk/idaps/CHADOX1%20NCOV-19
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how often the database of AstraZeneca covid vaccine side effects has been updated in each year since 2020.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Medicines and Healthcare products Regulatory Agency is responsible for monitoring all authorised medicines and vaccines in the United Kingdom, including the AstraZeneca COVID-19 vaccines, on an ongoing basis to ensure their benefits continue to outweigh any risks. This monitoring strategy is continuous, proactive, and based on a wide range of information sources, including reports of adverse events and rare side effects retrieved from the Yellow Card Database. A dedicated team of assessors reviews this information on a weekly basis to look for safety issues or unexpected, rare events.
The AstraZeneca COVID-19 vaccine no longer has an active market authorisation in the UK, since 2024. Consequently, no additional research activities have been undertaken beyond the ongoing monitoring of reported suspected adverse events through the Yellow Card Scheme. The most recent data extraction of spontaneous suspected adverse reactions reported via the Yellow Card Scheme was conducted on 20 September 2025. Further information is available at the following link:
https://yellowcard.mhra.gov.uk/idaps/CHADOX1%20NCOV-19
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to make (a) apheresis and (b) immunoabsorption treatments available for vaccine damage patients when doctors feel it would be beneficial.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
In the very rare event where an individual may have suffered a severe adverse reaction to a COVID-19 vaccine, care and treatment will be managed by National Health Service local specialist services, augmented as appropriate by national specialist advice, with any treatment dependent on the individual’s clinical needs.
The Government remains committed to research to improve the diagnosis and treatment in those rare cases where individuals may have suffered a severe adverse reaction to the COVID-19 vaccine.
Since the start of the pandemic, the National Institute for Health and Care Research (NIHR) has allocated more than £110 million of funding for COVID-19 vaccine research, including consideration of issues around vaccine safety. As part of this, the Department commissioned a £1.6 million programme of work through the NIHR, to understand the mechanisms underlying the occurrence of COVID-19 vaccine-induced thrombotic thrombocytopenia syndrome, a rare condition of blood clotting with low platelets following vaccination for COVID-19.
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to (a) approve and (b) fund specialist treatments for AstraZeneca vaccine damage.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
In the very rare event where an individual may have suffered a severe adverse reaction to a COVID-19 vaccine, care and treatment will be managed by National Health Service local specialist services, augmented as appropriate by national specialist advice, with any treatment dependent on the individual’s clinical needs.
The Government remains committed to research to improve the diagnosis and treatment in those rare cases where individuals may have suffered a severe adverse reaction to the COVID-19 vaccine.
Since the start of the pandemic, the National Institute for Health and Care Research (NIHR) has allocated more than £110 million of funding for COVID-19 vaccine research, including consideration of issues around vaccine safety. As part of this, the Department commissioned a £1.6 million programme of work through the NIHR, to understand the mechanisms underlying the occurrence of COVID-19 vaccine-induced thrombotic thrombocytopenia syndrome, a rare condition of blood clotting with low platelets following vaccination for COVID-19.
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what the rate for (a) approval of claims, (b) claims overturned at review and (c) payout has been for the Vaccine Damage Payment Scheme since March 2022.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Vaccine Damage Payment Scheme (VDPS) provides a one-off, tax-free payment of £120,000 to claimants who have been found, in rare cases and on the balance of probabilities, to have been severely disabled by certain vaccines for a disease listed in the Vaccine Damage Payments Act 1979.
As of 12 November 2025, data from NHS Business Service Authority (NHSBSA), the administrators of the VDPS, shows that since March 2022 there have been (a) 249 successful claims made through the scheme. Of these 249 successful claims, (b) 31 were as a result of the decision being overturned after review. The 249 successful claims amounted to a total of (c) £29,880,000 in payments.
Information on COVID-19 claims to the Vaccine Damage Payment Scheme is published on a quarterly basis by NHSBSA. Further information is available at the following link:
https://opendata.nhsbsa.net/dataset/vdps-covid-19
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what the medical experience requirements are for caseworkers handling vaccine damage payment claims.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Caseworkers supporting the Vaccine Damage Payment Scheme (VDPS) are administrative staff who are not involved in the assessment of claims. Their role is to provide claimants with a consistent point of contact, manage the administrative progress of claims, communicate updates, and ensure all necessary documentation is gathered. No medical experience is required for this supportive administrative function.
All clinical assessments under the VDPS are conducted solely by medical assessors. Medical assessors are General Medical Council registered doctors who have licences to practise and at least five years' experience and must have undertaken specialised training in vaccine damage and disability assessment.